Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:piperidinecarboxamide
go back to main search page
Accession:CHEBI:48592 term browser browse the term
Synonyms:related_synonym: piperidinecarboxamides


show annotations for term's descendants           Sort by:
 
(S)-ropivacaine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aifm1 apoptosis inducing factor, mitochondria associated 1 increases expression ISO Ropivacaine results in increased expression of AIFM1 protein CTD PMID:28079261 NCBI chr  X:135,304,063...135,343,062
Ensembl chr  X:135,304,066...135,343,087
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases response to substance
multiple interactions
ISO BCL2 protein results in decreased susceptibility to Ropivacaine
BCL2 protein inhibits the reaction [Ropivacaine results in increased cleavage of CASP3 protein]; BCL2 protein inhibits the reaction [Ropivacaine results in increased cleavage of PARP1 protein]
CTD PMID:15538973 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
decreases expression
ISO Ropivacaine results in increased cleavage of CASP3 protein
BCL2 protein inhibits the reaction [Ropivacaine results in increased cleavage of CASP3 protein]; CLU protein inhibits the reaction [Ropivacaine results in increased expression of CASP3 protein]
Ropivacaine results in decreased expression of CASP3 protein
CTD PMID:15538973, PMID:20194319 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp9 caspase 9 decreases expression ISO Ropivacaine results in decreased expression of CASP9 protein CTD PMID:20194319 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Clu clusterin multiple interactions
decreases expression
decreases response to substance
ISO CLU protein inhibits the reaction [Ropivacaine results in increased cleavage of PARP1 protein]; CLU protein inhibits the reaction [Ropivacaine results in increased expression of CASP3 protein]
Ropivacaine results in decreased expression of CLU protein
CLU protein results in decreased susceptibility to Ropivacaine
CTD PMID:15538973 NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
JBrowse link
G Hrh1 histamine receptor H 1 affects binding ISO HRH1 protein binds to Ropivacaine CTD PMID:32061592 NCBI chr 4:146,374,596...146,458,148
Ensembl chr 4:146,455,332...146,457,074
JBrowse link
G Itgam integrin subunit alpha M multiple interactions ISO Ropivacaine inhibits the reaction [TNF protein results in increased expression of [ITGAM protein binds to ITGB2 protein]] CTD PMID:9336308 NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
JBrowse link
G Itgb2 integrin subunit beta 2 multiple interactions ISO Ropivacaine inhibits the reaction [TNF protein results in increased expression of [ITGAM protein binds to ITGB2 protein]] CTD PMID:9336308 NCBI chr20:11,777,773...11,815,647
Ensembl chr20:11,777,783...11,815,647
JBrowse link
G Kcne1 potassium voltage-gated channel subfamily E regulatory subunit 1 multiple interactions ISO Ropivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein] CTD PMID:16931984 NCBI chr11:32,498,260...32,511,202
Ensembl chr11:32,498,261...32,508,420
JBrowse link
G Kcnq1 potassium voltage-gated channel subfamily Q member 1 decreases activity
multiple interactions
ISO Ropivacaine results in decreased activity of KCNQ1 protein
Ropivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein]
CTD PMID:16931984 NCBI chr 1:216,293,087...216,630,339
Ensembl chr 1:216,293,087...216,630,339
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
increases expression
multiple interactions
ISO Ropivacaine results in increased cleavage of PARP1 protein
Ropivacaine results in increased expression of PARP1 protein
BCL2 protein inhibits the reaction [Ropivacaine results in increased cleavage of PARP1 protein]; CLU protein inhibits the reaction [Ropivacaine results in increased cleavage of PARP1 protein]
CTD PMID:15538973, PMID:28079261 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Sell selectin L multiple interactions ISO Ropivacaine inhibits the reaction [TNF protein results in increased cleavage of SELL protein] CTD PMID:9336308 NCBI chr13:82,369,820...82,387,774
Ensembl chr13:82,369,493...82,387,631
JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 increases sulfation ISO SULT1A1 protein results in increased sulfation of Ropivacaine metabolite CTD PMID:10460806 NCBI chr 1:198,100,586...198,104,106
Ensembl chr 1:198,100,586...198,104,109
JBrowse link
G Sult1e1 sulfotransferase family 1E member 1 increases sulfation ISO SULT1E1 protein results in increased sulfation of Ropivacaine metabolite CTD PMID:10460806 NCBI chr14:22,070,861...22,089,264
Ensembl chr14:22,072,024...22,089,248
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO Ropivacaine inhibits the reaction [TNF protein results in increased cleavage of SELL protein]; Ropivacaine inhibits the reaction [TNF protein results in increased expression of [ITGAM protein binds to ITGB2 protein]] CTD PMID:9336308 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
bupivacaine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bax BCL2 associated X, apoptosis regulator increases expression
multiple interactions
ISO Bupivacaine results in increased expression of BAX protein
8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one promotes the reaction [[Glucose co-treated with Bupivacaine] results in increased expression of BAX protein]; [Glucose co-treated with Bupivacaine] results in increased expression of BAX protein
CTD PMID:31672611 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression
multiple interactions
ISO Bupivacaine results in decreased expression of BCL2 protein
8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one promotes the reaction [[Glucose co-treated with Bupivacaine] results in decreased expression of BCL2 protein]; [Glucose co-treated with Bupivacaine] results in decreased expression of BCL2 protein
CTD PMID:31672611 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Casp3 caspase 3 decreases expression
increases activity
ISO
EXP
Bupivacaine results in decreased expression of CASP3 protein
Bupivacaine results in increased activity of CASP3 protein
CTD PMID:16109997, PMID:20194319 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp9 caspase 9 decreases expression ISO Bupivacaine results in decreased expression of CASP9 protein CTD PMID:20194319 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 multiple interactions EXP [Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of CYP3A9 mRNA CTD PMID:22341215 NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
JBrowse link
G Entpd4 ectonucleoside triphosphate diphosphohydrolase 4 multiple interactions EXP [Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of ENTPD4 mRNA CTD PMID:22341215 NCBI chr15:51,222,954...51,250,787
Ensembl chr15:51,222,954...51,250,787
JBrowse link
G Hpgds hematopoietic prostaglandin D synthase increases expression ISO Bupivacaine results in increased expression of HPGDS mRNA; Bupivacaine results in increased expression of HPGDS protein CTD PMID:19359520 NCBI chr 4:95,945,356...95,970,666
Ensembl chr 4:95,946,025...95,970,666
JBrowse link
G Hrh1 histamine receptor H 1 affects binding ISO HRH1 protein binds to Bupivacaine CTD PMID:32061592 NCBI chr 4:146,374,596...146,458,148
Ensembl chr 4:146,455,332...146,457,074
JBrowse link
G Itgam integrin subunit alpha M increases expression
multiple interactions
ISO Bupivacaine results in increased expression of ITGAM mRNA
4-benzhydryloxy-1-(3-(1H-tetrazol-5-yl-)-propyl)piperidine inhibits the reaction [Bupivacaine results in increased expression of ITGAM mRNA]
CTD PMID:19359520 NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
JBrowse link
G Kcne1 potassium voltage-gated channel subfamily E regulatory subunit 1 multiple interactions ISO Bupivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein]; KCNE1 protein inhibits the reaction [KCNQ1 protein mutant form results in increased susceptibility to Bupivacaine] CTD PMID:16931984 NCBI chr11:32,498,260...32,511,202
Ensembl chr11:32,498,261...32,508,420
JBrowse link
G Kcnk9 potassium two pore domain channel subfamily K member 9 multiple interactions ISO Bupivacaine inhibits the reaction [KCNK9 protein results in increased transport of Potassium] CTD PMID:11249964 NCBI chr 7:113,894,918...113,938,397
Ensembl chr 7:113,903,557...113,937,941
JBrowse link
G Kcnq1 potassium voltage-gated channel subfamily Q member 1 multiple interactions
decreases activity
increases response to substance
ISO Bupivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein]; KCNE1 protein inhibits the reaction [KCNQ1 protein mutant form results in increased susceptibility to Bupivacaine]
Bupivacaine results in decreased activity of KCNQ1 protein
CTD PMID:16931984 NCBI chr 1:216,293,087...216,630,339
Ensembl chr 1:216,293,087...216,630,339
JBrowse link
G Myf5 myogenic factor 5 decreases expression EXP Bupivacaine results in decreased expression of MYF5 protein CTD PMID:10434046 NCBI chr 7:49,729,533...49,732,974
Ensembl chr 7:49,729,533...49,732,764
JBrowse link
G Myod1 myogenic differentiation 1 decreases expression EXP Bupivacaine results in decreased expression of MYOD1 protein CTD PMID:10434046 NCBI chr 1:102,396,538...102,399,248
Ensembl chr 1:102,396,538...102,399,248
JBrowse link
G Myog myogenin decreases expression EXP Bupivacaine results in decreased expression of MYOG protein CTD PMID:10434046 NCBI chr13:51,126,459...51,129,048
Ensembl chr13:51,126,459...51,129,048
JBrowse link
G Prkcb protein kinase C, beta multiple interactions EXP [Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of PRKCB mRNA CTD PMID:22341215 NCBI chr 1:192,233,569...192,575,339
Ensembl chr 1:192,233,910...192,574,831
JBrowse link
G Ptgdr prostaglandin D2 receptor affects expression ISO Bupivacaine affects the expression of PTGDR mRNA CTD PMID:19359520 NCBI chr15:19,195,606...19,196,508 JBrowse link
G Ptgs1 prostaglandin-endoperoxide synthase 1 increases expression ISO Bupivacaine results in increased expression of PTGS1 mRNA CTD PMID:18165598 NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
ISO Bupivacaine results in increased expression of PTGS2 mRNA
[Bupivacaine results in increased expression of PTGS2] which results in increased abundance of Dinoprostone
CTD PMID:18165598 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Slc6a2 solute carrier family 6 member 2 multiple interactions ISO Bupivacaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine] CTD PMID:16725121 NCBI chr19:15,391,682...15,431,274
Ensembl chr19:15,391,581...15,431,274
JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 increases activity
multiple interactions
EXP Bupivacaine results in increased activity of TRPV1 protein
Bupivacaine affects the reaction [Capsaicin results in increased activity of TRPV1 protein]
CTD PMID:15854744, PMID:18172555 NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
JBrowse link
G Xrcc6 X-ray repair cross complementing 6 increases expression
multiple interactions
ISO Bupivacaine results in increased expression of XRCC6 protein
8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one inhibits the reaction [[Glucose co-treated with Bupivacaine] results in increased expression of XRCC6 protein]; [Glucose co-treated with Bupivacaine] results in increased expression of XRCC6 protein; Glucose inhibits the reaction [Bupivacaine results in increased expression of XRCC6 protein]
CTD PMID:31672611 NCBI chr 7:123,259,881...123,280,613
Ensembl chr 7:123,259,761...123,280,612
JBrowse link
mepivacaine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Kcne1 potassium voltage-gated channel subfamily E regulatory subunit 1 multiple interactions ISO Mepivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein] CTD PMID:16931984 NCBI chr11:32,498,260...32,511,202
Ensembl chr11:32,498,261...32,508,420
JBrowse link
G Kcnq1 potassium voltage-gated channel subfamily Q member 1 decreases activity
multiple interactions
ISO Mepivacaine results in decreased activity of KCNQ1 protein
Mepivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein]
CTD PMID:16931984 NCBI chr 1:216,293,087...216,630,339
Ensembl chr 1:216,293,087...216,630,339
JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 increases activity EXP Mepivacaine results in increased activity of TRPV1 protein CTD PMID:18172555 NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19810
    chemical entity 19810
      atom 19808
        nonmetal atom 19683
          nitrogen atom 18565
            nitrogen molecular entity 18565
              organonitrogen compound 18335
                organonitrogen heterocyclic compound 17481
                  piperidines 7446
                    piperidinecarboxamide 30
                      (1-methylsulfonyl-4-piperidinyl)-(4-morpholinyl)methanone 0
                      (2S)-1-\{(2R)-2-[(8S,11S)-8-(2-amino-2-oxoethyl)-6,9-dioxo-2-oxa-7,10-diazabicyclo[11.2.2]heptadeca-1(15),13,16-trien-11-yl]-2-hydroxyethyl\}-N-tert-butylpiperidine-2-carboxamide 0
                      (2S)-N-tert-butylpiperidine-2-carboxamide 0
                      (3S)-1-[(E)-amino(imino)methyl]-N-(\{(2S)-1-[N-(2-naphthylsulfonyl)-L-seryl]pyrrolidin-2-yl\}methyl)piperidine-3-carboxamide 0
                      (S)-ropivacaine + 15
                      1-(2-chloro-4-pyrimidinyl)-4-piperidinecarboxamide 0
                      1-(4,6-dimethoxy-1,3,5-triazin-2-yl)-N-(thiophen-2-ylmethyl)-4-piperidinecarboxamide 0
                      1-(4-oxo-2-thieno[3,2-d][1,3]thiazinyl)-N-(phenylmethyl)-3-piperidinecarboxamide 0
                      1-(5-bromo-2-pyrimidinyl)-4-piperidinecarboxamide 0
                      1-(5-bromo-2-thiazolyl)-4-piperidinecarboxamide 0
                      1-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-N-(5-methyl-2-pyridinyl)-4-piperidinecarboxamide 0
                      1-[2-[3-(dimethylamino)phenyl]-4-pyrimidinyl]-4-piperidinecarboxamide 0
                      1-[4-(3,4,5-trimethoxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-(3-propan-2-yloxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-(4-aminophenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-(4-bromophenyl)-2-thiazolyl]-N-(3-phenylpropyl)-4-piperidinecarboxamide 0
                      1-[4-(4-bromophenyl)-2-thiazolyl]-N-(phenylmethyl)-4-piperidinecarboxamide 0
                      1-[4-(4-ethoxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-(4-phenylmethoxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-(4-propan-2-yloxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-(4-tert-butylphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-[4-(2-methylpropoxy)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-[4-(dimethylamino)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-[4-(methylthio)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[4-cyano-2-(2-furanyl)-5-oxazolyl]-4-piperidinecarboxamide 0
                      1-[5-[3-(dimethylamino)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-[5-[4-(methylthio)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                      1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide + 22
                      2-[2-[[[1-(1H-imidazol-5-ylsulfonyl)-3-piperidinyl]-oxomethyl]amino]-4-thiazolyl]acetic acid ethyl ester 0
                      4-\{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino\}-N-ethylpiperidine-1-carboxamide 0
                      N-(3-methylbutyl)-1-[(5-methyl-2-furanyl)methyl]-4-piperidinecarboxamide 0
                      N-(4-methylcyclohexyl)-1-(2-pyrazinyl)-4-piperidinecarboxamide 0
                      N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)piperidine-4-carboxamide 0
                      N-[(1R)-2-\{(2S)-2-[(3-carbamimidamidopropyl)carbamoyl]piperidin-1-yl\}-1-(cyclohexylmethyl)-2-oxoethyl]glycine 0
                      N-[(3-methoxyphenyl)methyl]-1-[(6-methyl-2,4-dioxo-1H-pyrimidin-5-yl)sulfonyl]-3-piperidinecarboxamide 0
                      N-[2-(3,4-diethoxyphenyl)ethyl]-1-[6-(4-morpholinyl)-3-pyridazinyl]-4-piperidinecarboxamide 0
                      N-[3-(1-azepanyl)propyl]-1-ethylsulfonyl-4-piperidinecarboxamide 0
                      N-[4-(4-methylphenyl)-2-thiazolyl]-1-thiophen-2-ylsulfonyl-4-piperidinecarboxamide 0
                      N-[6,6-dimethyl-5-[(1-methyl-4-piperidinyl)-oxomethyl]-1,4-dihydropyrrolo[3,4-c]pyrazol-3-yl]-3-methylbutanamide 0
                      N-tert-butyl-1-[[5-[2-(2-ethoxyphenyl)ethenyl]-3-methyl-1,2-oxazol-4-yl]sulfonyl]piperidine-4-carboxamide 0
                      [1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinyl]-(1-piperazinyl)methanone 0
                      mepivacaine + 3
                      mepivacaine hydrochloride 0
                      nipecotamide + 0
                      rac5c 0
                      ropivacaine + 15
Path 2
Term Annotations click to browse term
  CHEBI ontology 19810
    subatomic particle 19808
      composite particle 19808
        hadron 19808
          baryon 19808
            nucleon 19808
              atomic nucleus 19808
                atom 19808
                  main group element atom 19696
                    p-block element atom 19696
                      carbon group element atom 19599
                        carbon atom 19588
                          organic molecular entity 19588
                            organic group 18527
                              organic divalent group 18520
                                organodiyl group 18520
                                  carbonyl group 18427
                                    carbonyl compound 18427
                                      carboxylic acid 18108
                                        carboacyl group 17369
                                          univalent carboacyl group 17369
                                            carbamoyl group 17156
                                              carboxamide 17156
                                                monocarboxylic acid amide 14573
                                                  piperidinecarboxamide 30
                                                    (1-methylsulfonyl-4-piperidinyl)-(4-morpholinyl)methanone 0
                                                    (2S)-1-\{(2R)-2-[(8S,11S)-8-(2-amino-2-oxoethyl)-6,9-dioxo-2-oxa-7,10-diazabicyclo[11.2.2]heptadeca-1(15),13,16-trien-11-yl]-2-hydroxyethyl\}-N-tert-butylpiperidine-2-carboxamide 0
                                                    (2S)-N-tert-butylpiperidine-2-carboxamide 0
                                                    (3S)-1-[(E)-amino(imino)methyl]-N-(\{(2S)-1-[N-(2-naphthylsulfonyl)-L-seryl]pyrrolidin-2-yl\}methyl)piperidine-3-carboxamide 0
                                                    (S)-ropivacaine + 15
                                                    1-(2-chloro-4-pyrimidinyl)-4-piperidinecarboxamide 0
                                                    1-(4,6-dimethoxy-1,3,5-triazin-2-yl)-N-(thiophen-2-ylmethyl)-4-piperidinecarboxamide 0
                                                    1-(4-oxo-2-thieno[3,2-d][1,3]thiazinyl)-N-(phenylmethyl)-3-piperidinecarboxamide 0
                                                    1-(5-bromo-2-pyrimidinyl)-4-piperidinecarboxamide 0
                                                    1-(5-bromo-2-thiazolyl)-4-piperidinecarboxamide 0
                                                    1-[(3,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-N-(5-methyl-2-pyridinyl)-4-piperidinecarboxamide 0
                                                    1-[2-[3-(dimethylamino)phenyl]-4-pyrimidinyl]-4-piperidinecarboxamide 0
                                                    1-[4-(3,4,5-trimethoxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                                                    1-[4-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-2-thiazolyl]-4-piperidinecarboxamide 0
                                                    1-[4-(3-propan-2-yloxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                                                    1-[4-(4-aminophenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                                                    1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                                                    1-[4-(4-bromophenyl)-2-thiazolyl]-N-(3-phenylpropyl)-4-piperidinecarboxamide 0
                                                    1-[4-(4-bromophenyl)-2-thiazolyl]-N-(phenylmethyl)-4-piperidinecarboxamide 0
                                                    1-[4-(4-ethoxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                                                    1-[4-(4-phenylmethoxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                                                    1-[4-(4-propan-2-yloxyphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                                                    1-[4-(4-tert-butylphenyl)-2-thiazolyl]-4-piperidinecarboxamide 0
                                                    1-[4-[4-(2-methylpropoxy)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                                                    1-[4-[4-(dimethylamino)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                                                    1-[4-[4-(methylthio)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                                                    1-[4-cyano-2-(2-furanyl)-5-oxazolyl]-4-piperidinecarboxamide 0
                                                    1-[5-[3-(dimethylamino)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                                                    1-[5-[4-(methylthio)phenyl]-2-thiazolyl]-4-piperidinecarboxamide 0
                                                    1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide + 22
                                                    2-[2-[[[1-(1H-imidazol-5-ylsulfonyl)-3-piperidinyl]-oxomethyl]amino]-4-thiazolyl]acetic acid ethyl ester 0
                                                    4-\{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino\}-N-ethylpiperidine-1-carboxamide 0
                                                    N-(3-methylbutyl)-1-[(5-methyl-2-furanyl)methyl]-4-piperidinecarboxamide 0
                                                    N-(4-methylcyclohexyl)-1-(2-pyrazinyl)-4-piperidinecarboxamide 0
                                                    N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)piperidine-4-carboxamide 0
                                                    N-[(1R)-2-\{(2S)-2-[(3-carbamimidamidopropyl)carbamoyl]piperidin-1-yl\}-1-(cyclohexylmethyl)-2-oxoethyl]glycine 0
                                                    N-[(3-methoxyphenyl)methyl]-1-[(6-methyl-2,4-dioxo-1H-pyrimidin-5-yl)sulfonyl]-3-piperidinecarboxamide 0
                                                    N-[2-(3,4-diethoxyphenyl)ethyl]-1-[6-(4-morpholinyl)-3-pyridazinyl]-4-piperidinecarboxamide 0
                                                    N-[3-(1-azepanyl)propyl]-1-ethylsulfonyl-4-piperidinecarboxamide 0
                                                    N-[4-(4-methylphenyl)-2-thiazolyl]-1-thiophen-2-ylsulfonyl-4-piperidinecarboxamide 0
                                                    N-[6,6-dimethyl-5-[(1-methyl-4-piperidinyl)-oxomethyl]-1,4-dihydropyrrolo[3,4-c]pyrazol-3-yl]-3-methylbutanamide 0
                                                    N-tert-butyl-1-[[5-[2-(2-ethoxyphenyl)ethenyl]-3-methyl-1,2-oxazol-4-yl]sulfonyl]piperidine-4-carboxamide 0
                                                    [1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinyl]-(1-piperazinyl)methanone 0
                                                    mepivacaine + 3
                                                    mepivacaine hydrochloride 0
                                                    nipecotamide + 0
                                                    rac5c 0
                                                    ropivacaine + 15
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.